bluebird bio Revenue and Competitors
Estimated Revenue & Valuation
- bluebird bio's estimated annual revenue is currently $53.6M per year.
- bluebird bio received $632.5M in venture funding in July 2018.
- bluebird bio's estimated revenue per employee is $97,901
- bluebird bio's total funding is $484M.
- bluebird bio's current valuation is $612M. (January 2022)
Employee Data
- bluebird bio has 548 Employees.
- bluebird bio grew their employee count by -22% last year.
bluebird bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 73 | -39% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $3.1M | 26 | 63% | N/A | N/A |
#4 | $29.6M | 125 | 18% | $351M | N/A |
#5 | $15.8M | 84 | -18% | $312.8M | N/A |
#6 | $0.5M | 7 | 17% | N/A | N/A |
#7 | $235M | 269 | -43% | $340.9M | N/A |
#8 | $2.2M | 28 | 4% | N/A | N/A |
#9 | $0.6M | 10 | -9% | N/A | N/A |
#10 | $0.5M | 9 | 29% | N/A | N/A |
What Is bluebird bio?
We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$484M
Total Funding
548
Number of Employees
$53.6M
Revenue (est)
-22%
Employee Growth %
$612M
Valuation
N/A
Accelerator
bluebird bio News
Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...
Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...
The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...
bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $75M | 555 | 3% | N/A |
#2 | $106.6M | 565 | 9% | N/A |
#3 | $110.3M | 570 | 13% | N/A |
#4 | $156.8M | 575 | 3% | N/A |
#5 | $148.9M | 584 | 4% | N/A |
bluebird bio Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-04-21 | $30.0M | Undisclosed | ARCH Venture Partners, Third Rock Ventures | Article |
| 2012-07-26 | $60.0M | D | Deerfield Partners, RA Capital | Article |
| 2013-06-03 | $60.0M | D | Deerfield Partners, RA Capital | Article |
| 2014-12-17 | $150.0M | Undisclosed | Article | |
| 2015-06-25 | $575.0M | BofA Merrill Lynch | Article | |
| 2016-12-08 | $200.0M | Undisclosed | Goldman, Sachs & Co | Article |
| 2017-06-28 | $350.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2017-12-14 | $600.0M | Undisclosed | Multiple | Article |
| 2018-01-10 | $651.3M | Undisclosed | Multiple | Article |
| 2018-07-25 | $632.5M | Undisclosed | Multiple | Article |